NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2080225144

Registered date:30/03/2020

Basic Information

Recruitment status completed
Health condition(s) or Problem(s) studied
Date of first enrollment09/06/2020
Target sample size500
Countries of recruitmentJapan,North America
Study typeInterventional
Intervention(s)investigational material(s) Generic name etc : INN of investigational material : pembrolizumab, lenvatinib, Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : pembrolizumab, - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcomeefficacy
Secondary Outcomesafety efficacy

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria
Exclude criteria

Related Information

Contact

Public contact
Name
Address
Telephone -
E-mail JPCT@merck.com
Affiliation
Scientific contact
Name
Address
Telephone -
E-mail JPCT@merck.com
Affiliation